Other headlines:ACR Image Metrix plans to support PET/CT Bone trial
Siemens unveiled this week an ultrasound catheter that delivers real-time 3D images from inside the heart. The company is framing the new product as the world's first volume intracardiac echocardiography (VICE) catheter. Shown May 13 to 16 at the Heart Rhythm Society meeting in Boston, the Acuson AcuNav V promises to improve therapeutic ablation procedures and other electrophysiology applications. The VICE catheter is the latest such device in the AcuNav family, which entered the market 10 years ago.
Researchers in a multicenter trial comparing the effectiveness of PET/CT and conventional nuclear medicine to detect cancer metastases in the bone will depend on a data and image storage infrastructure developed by the American College of Radiology Image Metrix. Siemens and the Academy of Molecular Imaging are sponsoring the trial, which will compare results from planar technetium-99m MDP (methylene diphosphonate) bone imaging with fluorine-18 sodium fluoride PET/CT (F-18 NaF) in the detection of bony metastases from breast, prostate, and non-small cell lung cancers. Final results will be tallied on 500 patients studied at 13 sites in the U.S. using a protocol developed with the FDA and Centers for Medicare and Medicaid Services. The first subjects of this patient population have been enrolled at the University of California, Los Angeles Medical Center, VA Greater Los Angeles Healthcare Systems, and Scottsdale Medical Imaging. More than two million planar Tc-99m MDP scans are done each year to determine whether cancer has spread to the bone. F-18 NaF PET/CT bone scanning may have advantages, as it can find smaller metastases and differentiate more accurately between cancerous and noncancerous lesions.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.